Monthly information on share capital and company voting rights
13 Juni 2023 - 10:30PM
Monthly information on share capital and company voting rights
Listing market: Euronext Growth
ISIN code: FR0010425595
Date |
Total number of sharesin the
capital |
Total number of voting rights |
05/31/2023 |
55,583,768 |
61,505,063 |
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
23 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS). For more information, visit www.cellectis.com. Follow
Cellectis on social media: @cellectis, LinkedIn and
YouTube
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,”
“could,” “would” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management, including
information provided or otherwise publicly reported by our licensed
partners. Forward-looking statements include statements about
advancement, timing and progress of clinical trials (including with
respect to patient enrollment and follow-up), the timing of our
presentation of data and submission of regulatory filings, the
adequacy of our supply of clinical vials, the operational
capabilities at our manufacturing facilities, the sufficiency of
cash to fund operations, the adequacy and continuity of supply of
clinical supply and alemtuzumab, the ability of an anti-CD52 as
alemtuzumab to improve any efficacy and the potential benefit of
UCART product candidates. These forward-looking statements are made
in light of information currently available to us and are subject
to numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development. With respect to our cash runway, our operating plans,
including product development plans, may change as a result of
various factors, including factors currently unknown to us.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2022 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information, please
contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.com
Investor Relation contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430
7577
- Voting_Rights_PR_May 2023_EN_docx
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024